by David Wallace Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide deeper molecular responses and more durable disease control for some patients with high-risk essential thrombocythemia (ET). The findings were presented by Harinder Gill, MD, at the 2026 European Hematology Association Congress in Stockholm. What Did […]
BESREMi, Ropeginterferon FDA approved Treatment for PV
by David Wallace Patients are Asking – MPN Expert Dr. Ghaith Abu-Zeinah discusses Ropeginterferon (BESREMi), new Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat polycythemia vera. Should I switch from Pegasys to the new FDA approved interferon? How might BESREMi change the treatment paradigm […]
MPN Clinical Trials 2021 Update
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials in 2021. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a Biologics License Application (BLA). Ropeginterferon and Pacritinib […]
Ropeginterferon Effective Treatment for Polycythemia Vera
Thrombotic Risk Reduction and High Rate of Complete Molecular Response with the Long Term Use of Ropeg interferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study, ASH 2019 interview with Dr. Kiladjian by David Wallace Dr. Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter […]